睾酮5-α还原酶Ⅱ基因V89L多态性与前列腺癌预后关系的研究  

V89L polymorphism of the testosterone 5-alpha-reductase Ⅱ gene and prognostic factors of prostate cancer

作　　者：佟明[1] 金艳阳[1] 李刚[1] 刘四明[1] 吉春冬[1] 

机构地区：[1]辽宁医学院附属第一医院泌尿外科,辽宁锦州121001

出　　处：《中华男科学杂志》2010年第11期990-993,共4页National Journal of Andrology

摘　　要：目的:探讨睾酮5-α还原酶Ⅱ(SRD5A2)基因V89L多态性与影响前列腺癌预后因素的关系。方法:对V89L多态性位点用Rsa-1限制性内切酶进行酶切鉴定,观察112例前列腺癌患者和89例BPH患者的V89L(VV、VL、LL)多态性分布情况的差异及其多态性与前列腺癌患者年龄、前列腺特异性抗原(PSA)、游离PSA/总PSA值(tPSA/fPSA,F/T)、Gleason评分、临床分期的关系。结果:前列腺癌组112例与BPH组89例的V89L基因频度风险无显著性差异(χ2=3.606,df=2,P=0.165)。前列腺癌组VV和VL+LL基因型与fPSA、tPSA、F/T、T分期、Gleason评分差异无显著性(P>0.05)。VV和VL+LL各评价预后指标差异无显著性(P>0.05)。分段评价PSA水平、Gleason评分、临床分期、年龄,均与两种基因型无相关性(P>0.05)。结论:V89L多态性与预后无明显关系,但是可能与前列腺癌的风险存在间接的关系。Objective：To investigate the association of V89L polymorphism of the SRD5A2 gene with the prognostic factors of prostate cancer（PCa）.Methods：We identified the V89L polymorphic sites of the SRD5A2 gene after Rsa-1 restriction enzyme digestion,observed the distribution of V89L（VV,VL and LL）polymorphism in 112 PCa and 89 benign prostate hyperplasia（BPH）patients,and determined the association of V89L polymorphism with the age,free PSA（fPSA）,total PSA（tPSA）,fPSA/tPSA ratio,tumor stage and Gleason score of the PCa patients.Results：No statistically significant differences were found in the V89L polymorphism-induced genetic risk frequencies between the PCa and BPH groups（χ2 = 3.606,df = 2,P = 0.165）,nor any significant correlation between the genotypes of VV and VL＋LL and the differences in the fPSA,tPSA,fPSA/tPSA ratio,tumor stage,Gleason score and age of the PCa patients.VV and VL＋LL showed no obvious association with the prognostic factors of PCa.Conclusion：V89L polymorphism is not related with the prognosis of PCa,but may be indirectly associated with its risk.

关 键 词：睾酮5-α还原酶Ⅱ 前列腺癌 基因 多态性 

分 类 号：R737.25[医药卫生—肿瘤]